Oncotype DX 21基因检测在ER阳性早期乳腺癌中的应用
发布时间：2018-10-19 12:10
【摘要】：在诸多评估雌激素受体(estrogen receptor,ER)阳性早期乳腺癌复发风险的多基因工具中,Oncotype DX 21基因检测因其独特的疗效预测作用而被广泛应用于淋巴结阴性患者。多项回顾性研究已证明其在淋巴结阳性人群同样具有预后预测价值,但前瞻性临床试验证据仍不充分。该检测能协同其他重要临床病理因素,影响乳腺癌患者的辅助治疗方案,且具较高的成本效益。该研究就21基因检测对早期乳腺癌患者的预后预测价值、独特优势、辅助治疗决策影响、成本效果和现存争议进行综述。
[Abstract]:The detection of, Oncotype DX 21 gene has been widely used in lymph node negative patients due to its unique predictive effect of estrogen receptor (estrogen receptor,ER) positive early breast cancer recurrence risk. A number of retrospective studies have shown that it also has prognostic value in lymphaden-positive populations, but the evidence in prospective clinical trials is still insufficient. It can be combined with other important clinicopathological factors to influence the adjuvant treatment of breast cancer patients and is cost-effective. This study reviewed the prognostic value, unique advantages, effect of adjuvant therapy decision, cost effectiveness and current controversy of 21 gene detection in patients with early breast cancer.
【作者单位】： 复旦大学附属肿瘤医院乳腺外科复旦大学上海医学院肿瘤学系;
【分类号】：R737.9
，
本文编号：2281072
[Abstract]:The detection of, Oncotype DX 21 gene has been widely used in lymph node negative patients due to its unique predictive effect of estrogen receptor (estrogen receptor,ER) positive early breast cancer recurrence risk. A number of retrospective studies have shown that it also has prognostic value in lymphaden-positive populations, but the evidence in prospective clinical trials is still insufficient. It can be combined with other important clinicopathological factors to influence the adjuvant treatment of breast cancer patients and is cost-effective. This study reviewed the prognostic value, unique advantages, effect of adjuvant therapy decision, cost effectiveness and current controversy of 21 gene detection in patients with early breast cancer.
【作者单位】： 复旦大学附属肿瘤医院乳腺外科复旦大学上海医学院肿瘤学系;
【分类号】：R737.9
，
本文编号：2281072
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2281072.html
